

**For Immediate Release**  
07 May 2007



## **Forbion Capital Partners adds top tier investors to its investor base**

### ***New investors validate the independent Forbion Team***

**Naarden, The Netherlands, 7<sup>th</sup> May 2007** – Forbion Capital Partners announced today that its has completed the syndication of part of Collier Capital's position in the Forbion Capital Fund I (Forbion I)

Collier Capital, the largest investor in Forbion I, has syndicated an undisclosed part of its position to seven new Limited Partners, in accordance with its earlier intentions announced in January 2007 when it had underwritten a 75% holding in Forbion I. This pre-agreed syndication process was aimed at significantly diversifying the investor base of Forbion Capital Partners, which spun out of ABN AMRO in December 2006.

Through the syndication, Collier Capital and ABN AMRO, Forbion's cornerstone investors, are joined by seven additional leading private equity investors: HarbourVest; Partners Group; Hamilton Lane; Pomona Capital; Van Herk Investments; Von Braun & Schreiber Private Equity Partners and Indofin Group. The offering was significantly oversubscribed at 3.5 times.

"We're delighted to have such respected, knowledgeable investors join the Forbion Capital Fund," said Bart Bergstein, Managing Partner at Forbion. "The entry of this investor group, not only validates the quality of our team and the prospects of the current portfolio, it also creates a strong investor base for future funds."

The Forbion Capital Fund is a EUR 200 M fund that is fully dedicated to life sciences. It assumed investments of EUR 90 M in 26 companies upon its formation in December 2006, leaving ample room for new and follow-on investments. Forbion invests in drug development companies and in medical technologies, both in Europe and the US.

Forbion anticipates making initial investments from EUR 3 M to EUR 7 M, with the potential for follow-on investments. In addition to providing finance to investee companies, the Forbion team works closely with entrepreneurs, industry experts and academic institutions to accelerate the development of its companies and to optimise value creation toward an exit.

The Forbion Capital Partners management team is founded from the original ABN AMRO Capital Life Sciences team (AAC LS team). This team represents a wealth of knowledge and experience from scientific, financial and business backgrounds. Over the past seven years the Forbion team, as AAC LS, has made more than 30 investments across Europe and the US, resulting in top-quartile cash on cash returns. During this period the members of the team have served on the Board of Directors of nearly all the portfolio companies. Recent accomplishments for the Forbion team include leading the series B EUR 40 M fundraising of Santaris Pharma, A/S as well as the EUR 22 M series A investment in Amsterdam Molecular Therapeutics and the EUR 13 M series B round of PanGenetics BV.

**- Ends -**

**Media enquiries:****Northbank Communications:**

Annabel Entress, +44 (0)207 268 3002 / a.entress@northbankcommunications.com  
Adam Michael, +44 (0)207 268 3002 / a.michael@northbankcommunications.com

**For Forbion Capital Partners:**

Bart Bergstein, Managing Partner, +31 (0) 35 699 3010, bart.bergstein@forbion.com

**Notes to editors****About Forbion Capital Partners**

Forbion Capital Partners invests in EU and US Life Sciences companies with a focus on human health, developing world-class products and technologies. The Forbion team has made life sciences investments since 2000 as ABN AMRO Capital Life Sciences, the venture arm of ABN AMRO Bank NV. In December of 2006 the group became independent by broadening its investor base and changed its name to Forbion Capital Partners. Since 2000, the Forbion team has successfully divested a number of investments, leaving an active portfolio of 25 companies. Assets under management currently total over EUR 200 M.

For more information, please visit [www.forbion.com](http://www.forbion.com)

**About Collier Capital**

Collier Capital, founded in 1990, is the leading global investor in private equity secondaries – the purchase of original investors' stakes in private equity funds (venture capital, buyout and mezzanine) or the acquisition of portfolios of companies from corporate owners/backers. The firm has \$8 billion under management.

In April 2007, Collier Capital closed its fifth fund with commitments of \$4.5 billion from 200 international institutional investors. Collier International Partners V is the largest secondaries fund in the world. The firm invests anything from \$1 million to more than \$1 billion in individual transactions.

Collier Capital has interests in over 200 private equity funds and stakes in more than 2000 private companies throughout the world.

For more information, please visit [www.colliercapital.com](http://www.colliercapital.com)

**About ABN AMRO**

Netherlands-based ABN AMRO is a leading international bank with total assets of €1055 bln (as of 31 March 2007). It has more than 4,500 branches in 53 countries, and has a staff of more than 110,000 full-time equivalents worldwide. ABN AMRO is listed on Euronext and the New York Stock Exchange.

**About HarbourVest**

HarbourVest Partners, LLC is an independent global private equity investment firm and an SEC registered investment advisor, providing vehicles for institutional investors to invest in the venture capital and buyout markets in the U.S., Europe, and elsewhere through primary partnerships, secondary purchases, and direct investments. HarbourVest and its subsidiaries have 165

employees, including 62 investment professionals deployed in Boston, London, and Hong Kong. In 25 years of investing in private equity, the team has committed more than \$15.7 billion to newly formed funds, representing relationships with 200 private equity managers. The team has also completed over \$3.8 billion in secondary purchases of partnership interests and invested \$2.7 billion directly in operating companies. To learn more about HarbourVest, visit [www.harbourvest.com](http://www.harbourvest.com).

This communication has been approved for issue in the United Kingdom by HarbourVest Partners (U.K.) Limited, which is regulated by the Financial Services Authority.

### **About Partners Group**

Partners Group is a global alternative asset management firm with over CHF 17 billion in private equity, private debt, private real estate, infrastructure and hedge fund investment programs under management. The firm manages a broad range of funds, structured products and customized portfolios for an international clientele of institutional investors, private banks and distribution partners. Partners Group is headquartered in Zug, Switzerland and has offices in New York, London, San Francisco, Singapore and Guernsey. The firm employs over 200 people, is listed on the SWX Swiss Exchange (symbol: PGHN) with a market capitalization of over CHF 4 billion and majority owned by its 34 partners & principals and its employees.

For more information, please visit [www.partnersgroup.net](http://www.partnersgroup.net)

### **About Hamilton Lane**

Hamilton Lane is an independent financial institution that provides discretionary and non-discretionary asset management services in private equity and hedge fund investments. Founded in 1991, Hamilton Lane has over 70 private equity employees operating out of offices in Philadelphia, San Francisco, London and Singapore.

For more information, please visit [www.hamiltonlane.com](http://www.hamiltonlane.com)

### **About Pomona Capital**

Founded in 1994, Pomona Capital is an international private equity firm that manages over \$4 billion in commitments across a series of secondaries funds, primary funds of funds and co-investment funds for a global group of 170 sophisticated investors. Pomona owns partnership interests in over 400 private equity funds, diversified across the entire spectrum of private equity, with investments in over 3,000 companies. Pomona's team is based in London and New York. Pomona's capital capacity and global reach is enhanced by a strategic partnership with the ING Group. For more information on Pomona Capital, visit [www.pomonacapital.com](http://www.pomonacapital.com).

### **About Van Herk Groep**

The Rotterdam-based Van Herk Group invests in real estate and in companies, focusing primarily on the Netherlands and the new EU member states. The Group began as a family business, and its history dates back more than half a century. The Van Herk Group participates in listed and non-listed companies and funds in primarily three sectors Biotech, Real-Estate and Energy.

More information is available at [www.vanherkgroep.nl](http://www.vanherkgroep.nl).

### **About Indofin Group**

The Indofin Group is a globally operating investment group with offices in Geneva, Houston, Paris and Rotterdam. Founded in 1968, the company is actively involved in the provision of private equity and the management of companies in Europe, the U.S., Canada, Australia and Asia, through minority and majority participations. The group is 100% owned by the De Bruin family.  
[www.indofin.com](http://www.indofin.com)